CA19-9-targeting monoclonal antibody

PreclinicalSmall molecule

CA19-9-targeting monoclonal antibody is one of 5 small molecule programs targeting Advanced Solid Cancers. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid CancersRecruiting

Advanced Solid CancersPreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Advanced Solid Cancers

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

3 2

Yervoy

Bristol-Myers Squibb

Phase 2

2 3

Copanlisib Hydrochloride

NNational Cancer Institute (NCI)

Phase 2

1 4

ND-003

SShenzhen NewDEL Biotech, Co., Ltd

Phase 1

1 5

CA19-9-targeting monoclonal antibody

BioNTech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalRecruiting

Advanced Solid Cancers

NCT07186842

Clinical

Trials by Indication[1]

Advanced Solid Cancers1 trial

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07186842·245 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CA19-9-targeting monoclonal antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CA19-9-targeting monoclonal antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CA19-9-targeting monoclonal antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BioNTech

CA19-9-targeting monoclonal antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Advanced Solid Cancers1 trial

References

Drug Info

Quick Facts

Related News